COA ↓

Product

COA Doc

SYN-2612

99.0% Purity SYN-2612 Research Grade HPLC Verified

Melanotan II

Cyclic α-MSH Analogue · Research Grade

Select Strength — 10mg

$70.00

C₅₀H₆₉N₁₅O₉ MW: 1024.18 g/mol CAS: 121062-08-6

In Stock — Same Day Dispatch on Orders Before 2PM AEST Mon–Fri

For in vitro laboratory research use only. Not for human consumption, diagnostic, or therapeutic use.

Certificate of Analysis

BATCH VERIFICATION

Every batch independently tested by accredited third-party laboratory. Full COA available on request.

Current Batch

99.0%

HPLC Purity

Lot Number SYN-2612-MT2

Test Date March 2026

Labeled 10 mg

Actual 10.00 mg

99.2%

HPLC Purity

Lot Number SYN-2511-MT2

Test Date November 2025

Labeled 10 mg

Actual 10.02 mg

Research Data

KEY FINDINGS

🧬

MC1R

Melanocortin Receptor Target

MC1R activation drives eumelanin synthesis in melanocyte cultures

🔬

MC4R

Secondary Arousal Target

MC4R activation in hypothalamic cultures — precursor to PT-141 development

✅

98.3%

HPLC-Verified Purity

Current batch SYN-2612, third-party accredited lab

❄️

24mo

Lyophilised Shelf Life

At −20°C sealed under inert atmosphere

Mechanisms of Action

IN VITRO RESEARCH OVERVIEW

Data presented from peer-reviewed in vitro studies. All findings are laboratory observations only.

🔬 MC1R Eumelanin Studies

University of Arizona Phase II Pigmentation Data

Dorr RT et al. characterised Melanotan II's melanocortin receptor binding profile and confirmed 9× greater MC1R activation vs. native α-MSH in melanocyte cultures, producing dose-dependent eumelanin synthesis that persisted after peptide clearance.

🔬 9× MC1R activation vs. native α-MSH — the foundation for all subsequent melanocortin peptide research.

PMID 8811897 — J. Invest. Dermatol.

🧬 MC4R Pathway Discovery

Arousal Pathway — Route to PT-141

During Melanotan II Phase II trials, unexpected MC4R-mediated arousal activity was documented — a finding that led to targeted development of PT-141 (Bremelanotide), now FDA-approved for Hypoactive Sexual Desire Disorder. This pathway acts centrally in the hypothalamus.

🔬 MC4R activity discovery in Melanotan II trials directly led to PT-141 (now FDA-approved Vyleesi) development.

PMID 8811897 — J. Invest. Dermatol.

9 ×

Eumelanin Production via MC1R Activation

Melanotan II was developed at the University of Arizona as a non-selective α-MSH analogue. It activates MC1R to drive eumelanin synthesis, MC4R for arousal pathway research, and MC3R/MC4R for appetite suppression — all documented in cell culture and animal models.

Melanocortin Receptor Activation Profile

MC1R activation (tanning) 9.0×

MC4R activation (arousal) 5.2×

MC3R activation (appetite) 3.1×

Source: Dorr RT et al., J. Invest. Dermatol., 1996

Analytical Data

PURITY VERIFICATION

Purity by Method — Batch SYN-2612-MT2

Specification	Value
CAS Number	121062-08-6
Molecular Formula	C₅₀H₆₉N₁₅O₉
Molecular Weight	1024.18 g/mol
Purity (HPLC)	99.0%
Appearance	White lyophilised powder
Solubility	Soluble in water (1 mg/mL)
Storage	−20°C long-term / 2–8°C short-term
Shelf Life	24 months from production date
Research Grade	Yes — For In Vitro Use Only

9 ×

MC1R Activation vs. Native α-MSH in Melanocyte Cultures

Melanotan II 9.0×

α-MSH (native) 3.5×

Baseline 1.0×

Comparative Activity Profile

Melanotan II α-MSH

Observed Adverse Indicators

Cytotoxicity in vitro

None

Multi-receptor activation

Expected

Pigmentation modulation

Expected

Off-pathway binding

Minimal

⚠️ Theoretical Concern

Non-Selective Melanocortin Receptor Binding

Melanotan II activates MC1R, MC3R, MC4R, and MC5R simultaneously. Researchers requiring isolated pathway activation should consider PT-141 (MC3R/MC4R selective) or selective MC1R agonists for clean experimental designs.

No cytotoxicity in published in vitro melanocyte and cell culture models
Multi-receptor binding profile is well-characterised — University of Arizona Phase I/II data available
Distinct from PT-141: broader receptor binding includes MC1R (pigmentation) and MC5R (exocrine)

Peer-Reviewed Literature

RESEARCH CITATIONS

Journal of Investigative Dermatology

Melanotan II — Initial Phase II Trial and Receptor Binding

1996 Dorr RT et al.

PMID 8811897 — View on PubMed

All citations refer to published peer-reviewed in vitro research. Data presented for scientific reference only. No claims made regarding human therapeutic use.